Oncomed Pharma (OMED) 12.57 $OMED
OncoMed Management to Present at Two Upcoming Investment Conferences
GlobeNewswire - Mon Jun 06, 7:00AM CDT
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, including anti-cancer stem cell and immuno-oncology product candidates, today announced that company management will participate in the following upcoming investor conferences:
OMED: 12.57 (+0.44)
OncoMed Presents Phase 1b Data for First-in-Class Treatments in Ovarian, Breast and Lung Cancer at the 2016 ASCO Annual Meeting
GlobeNewswire - Sun Jun 05, 8:00AM CDT
First Presentation of Combination Data for Wnt Inhibitors, Ipafricept and Vantictumab
OMED: 12.57 (+0.44)
OncoMed Pharmaceuticals Announces First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:04PM CDT
OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT
OMED: 12.57 (+0.44)
Ligand (LGND) Tops Q1 Earnings, Revenues, Updates View
Arpita Dutt - Zacks Investment Research - Thu May 05, 8:36AM CDT
In addition to announcing first quarter results, Ligand (LGND) announced the acquisition of economic rights to several programs owned by CorMatrix.
CBM: 51.35 (-1.06), OMED: 12.57 (+0.44), LGND: 137.72 (+2.84), ANIK: 51.80 (+1.88)
Nektar (NKTR) Reports Narrower-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:06PM CDT
Nektar (NKTR) reported a narrower-than-expected loss of 14 cents in the first quarter on revenues of $58.9 million.
OMED: 12.57 (+0.44), AZN: 33.91 (-0.23), BXLT: 46.02 (-0.18), NKTR: 17.79 (+0.50)
Illumina (ILMN) Misses on Q1 Earnings, Lowers '16 Guidance
Zacks Equity Research - Zacks Investment Research - Wed May 04, 7:33AM CDT
Illumina Inc. (ILMN) reported adjusted earnings per share (EPS) of 71 cents in the first quarter of 2016.
CBM: 51.35 (-1.06), OMED: 12.57 (+0.44), ANIP: 61.15 (+0.55), ILMN: 169.58 (+3.23)
OncoMed Pharmaceuticals to Report Financial Results for the First Quarter 2016 on Thursday, May 5, 2016
GlobeNewswire - Fri Apr 29, 7:30AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, including anti-cancer stem cell and immuno-oncology product candidates, will announce financial results for the quarter ended March 31, 2016 on Thursday, May 5, 2016. Paul J. Hastings, Chairman and Chief Executive Officer, will host a conference call to review first quarter results and recent corporate events beginning at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
OMED: 12.57 (+0.44)
Intellia Therapeutics Appoints Perry Karsen as Chairman of Its Board of Directors
BusinessWire - Fri Apr 22, 4:00PM CDT
Intellia Therapeutics, Inc., a leading gene-editing company, has named Perry Karsen as the Chairman of its Board of Directors.
VYGR: 14.81 (+0.07), OMED: 12.57 (+0.44), GSK: 45.24 (+0.17), BMY: 75.90 (+1.09), CELGZ: 1.13 (-0.03)
OncoMed Announces Clinical Data to be Presented at the 2016 ASCO Annual Meeting
GlobeNewswire - Thu Apr 21, 3:27PM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced today it will present data from several clinical programs at the upcoming American Society of Clinical Oncology (ASCO) 2016 Annual Meeting being held June 3-7, 2016 in Chicago, IL.
OMED: 12.57 (+0.44)
OncoMed Presents Biomarker Research for Two Clinical Programs and Demcizumab Mechanism Data at the AACR Annual Meeting 2016
GlobeNewswire - Wed Apr 20, 7:30AM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new biomarker research associated with its clinical programs for anti-RSPO3 (OMP-131R10) and vantictumab (anti-FZD7, OMP-18R5), as well as new preclinical mechanism-of-action data for demcizumab (anti-DLL4, OMP-18M21), at the American Association of Cancer Research (AACR) Meeting. All three presentations support ongoing clinical trials: anti-RSPO3 in a Phase1a/b trial in advanced solid tumor and colorectal cancer; vantictumab in a Phase 1b trial in pancreatic cancer; and demcizumab in a Phase 2 randomized study in first-line non-small cell lung cancer (NSCLC).
OMED: 12.57 (+0.44)
OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016
GlobeNewswire - Tue Apr 19, 8:00AM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new data related to its GITRL-Fc immuno-oncology therapeutic candidate at the American Association of Cancer Research (AACR) Meeting. OncoMed plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its GITRL-Fc candidate in late 2016/early 2017.
OMED: 12.57 (+0.44)
OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial for Demcizumab and Pembrolizumab (anti-PD1)
GlobeNewswire - Thu Mar 17, 7:30AM CDT
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced dosing of the first patient in its Phase 1b clinical trial of OncoMed's investigational agent demcizumab (anti-DLL4, OMP-21M18), with Merck's anti-Programmed Cell Death 1 (PD1) therapy pembrolizumab (KEYTRUDA(R)). The combination of these agents may act as a double blockade for cancer-induced immune suppression with potential application to a number of solid tumor cancers.
OMED: 12.57 (+0.44)
OncoMed to Present Data at the American Association of Cancer Research Annual Meeting 2016
GlobeNewswire - Wed Mar 16, 3:30PM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical anti-cancer stem cell and immuno-oncology therapeutic candidates in a total of five presentations at the upcoming American Association of Cancer Research (AACR) Meeting to be held April 16-20, 2016 in New Orleans, LA.
OMED: 12.57 (+0.44)
Why OncoMed Pharmaceuticals (OMED) Stock Might be a Great Pick
Zacks Equity Research - Zacks Investment Research - Mon Feb 01, 7:45AM CST
OncoMed Pharmaceuticals (OMED) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
OMED: 12.57 (+0.44)
OncoMed Tanks on Phase II Pancreatic Cancer Study Update
Zacks Equity Research - Zacks Investment Research - Wed Jan 27, 1:30PM CST
OncoMed Pharmaceuticals' (OMED) shares plunged 45% after it provided disappointing update on its pancreatic cancer candidate tarextumab.
OMED: 12.57 (+0.44), BXLT: 46.02 (-0.18), GSK: 45.24 (+0.17), ANIK: 51.80 (+1.88)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of OncoMed Pharmaceuticals, Inc.
BusinessWire - Mon Jan 25, 12:36PM CST
Levi & Korsinsky announces it has commenced an investigation of OncoMed Pharmaceuticals, Inc. (NASDAQGS: OMED) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
OMED: 12.57 (+0.44)
Why OncoMed Pharmaceuticals' Stock Crashed Today
George Budwell, The Motley Fool - Motley Fool - Mon Jan 25, 11:53AM CST
What : Shares of OncoMed Pharmaceuticals , a clinical-stage biotech, dropped by more than 46% today on heavy volume after an independent data safety monitoring board reported that the company's midstage pancreatic cancer drug, tarextumab, doesn't...
OMED: 12.57 (+0.44), GSK: 45.24 (+0.17)
Will 2016 Be Celgene Corporation's Best Year Yet?
Sean Williams, The Motley Fool - Motley Fool - Mon Jan 25, 9:38AM CST
Image source: NIH Image Gallery via Flickr. In a year in which the stock market was relatively flat, biotech blue-chip Celgene was a noted outperformer, having gained 5.5% over the 12 months. 2015 was yet another strong year of growth for the...
OMED: 12.57 (+0.44), CELG: 114.57 (+2.38)
OncoMed Provides Update on Tarextumab Phase 2 Pancreatic Cancer ALPINE Trial
GlobeNewswire - Mon Jan 25, 6:30AM CST
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, announced an update on the Phase 2 ALPINE clinical trial following a pre-planned January 23 interim efficacy assessment of the clinical trial by an independent data safety monitoring board (DSMB). The DSMB assessed data from 172 patients treated as of a January 6, 2016 data cutoff date.
OMED: 12.57 (+0.44)
OncoMed Presents Updated Phase 1b Data for Demcizumab in First-Line Pancreatic Cancer at the Gastrointestinal Cancers Symposium
GlobeNewswire - Fri Jan 22, 7:30AM CST
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, announced updated survival data from the company's Phase 1b clinical trial of demcizumab (anti-DLL4, OMP-21M18) at the Gastrointestinal Cancers Symposium.
OMED: 12.57 (+0.44)
OncoMed Management to Present at Two Upcoming Investment Conferences
GlobeNewswire - Mon Jun 06, 7:00AM CDT
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, including anti-cancer stem cell and immuno-oncology product candidates, today announced that company management will participate in the following upcoming investor conferences:
OMED: 12.57 (+0.44)
OncoMed Presents Phase 1b Data for First-in-Class Treatments in Ovarian, Breast and Lung Cancer at the 2016 ASCO Annual Meeting
GlobeNewswire - Sun Jun 05, 8:00AM CDT
First Presentation of Combination Data for Wnt Inhibitors, Ipafricept and Vantictumab
OMED: 12.57 (+0.44)
OncoMed Pharmaceuticals Announces First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:04PM CDT
OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT
OMED: 12.57 (+0.44)
Ligand (LGND) Tops Q1 Earnings, Revenues, Updates View
Arpita Dutt - Zacks Investment Research - Thu May 05, 8:36AM CDT
In addition to announcing first quarter results, Ligand (LGND) announced the acquisition of economic rights to several programs owned by CorMatrix.
CBM: 51.35 (-1.06), OMED: 12.57 (+0.44), LGND: 137.72 (+2.84), ANIK: 51.80 (+1.88)
Nektar (NKTR) Reports Narrower-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Wed May 04, 2:06PM CDT
Nektar (NKTR) reported a narrower-than-expected loss of 14 cents in the first quarter on revenues of $58.9 million.
OMED: 12.57 (+0.44), AZN: 33.91 (-0.23), BXLT: 46.02 (-0.18), NKTR: 17.79 (+0.50)
Illumina (ILMN) Misses on Q1 Earnings, Lowers '16 Guidance
Zacks Equity Research - Zacks Investment Research - Wed May 04, 7:33AM CDT
Illumina Inc. (ILMN) reported adjusted earnings per share (EPS) of 71 cents in the first quarter of 2016.
CBM: 51.35 (-1.06), OMED: 12.57 (+0.44), ANIP: 61.15 (+0.55), ILMN: 169.58 (+3.23)
OncoMed Pharmaceuticals to Report Financial Results for the First Quarter 2016 on Thursday, May 5, 2016
GlobeNewswire - Fri Apr 29, 7:30AM CDT
OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical development-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, including anti-cancer stem cell and immuno-oncology product candidates, will announce financial results for the quarter ended March 31, 2016 on Thursday, May 5, 2016. Paul J. Hastings, Chairman and Chief Executive Officer, will host a conference call to review first quarter results and recent corporate events beginning at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).
OMED: 12.57 (+0.44)
Intellia Therapeutics Appoints Perry Karsen as Chairman of Its Board of Directors
BusinessWire - Fri Apr 22, 4:00PM CDT
Intellia Therapeutics, Inc., a leading gene-editing company, has named Perry Karsen as the Chairman of its Board of Directors.
VYGR: 14.81 (+0.07), OMED: 12.57 (+0.44), GSK: 45.24 (+0.17), BMY: 75.90 (+1.09), CELGZ: 1.13 (-0.03)
OncoMed Announces Clinical Data to be Presented at the 2016 ASCO Annual Meeting
GlobeNewswire - Thu Apr 21, 3:27PM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) announced today it will present data from several clinical programs at the upcoming American Society of Clinical Oncology (ASCO) 2016 Annual Meeting being held June 3-7, 2016 in Chicago, IL.
OMED: 12.57 (+0.44)
OncoMed Presents Biomarker Research for Two Clinical Programs and Demcizumab Mechanism Data at the AACR Annual Meeting 2016
GlobeNewswire - Wed Apr 20, 7:30AM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new biomarker research associated with its clinical programs for anti-RSPO3 (OMP-131R10) and vantictumab (anti-FZD7, OMP-18R5), as well as new preclinical mechanism-of-action data for demcizumab (anti-DLL4, OMP-18M21), at the American Association of Cancer Research (AACR) Meeting. All three presentations support ongoing clinical trials: anti-RSPO3 in a Phase1a/b trial in advanced solid tumor and colorectal cancer; vantictumab in a Phase 1b trial in pancreatic cancer; and demcizumab in a Phase 2 randomized study in first-line non-small cell lung cancer (NSCLC).
OMED: 12.57 (+0.44)
OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016
GlobeNewswire - Tue Apr 19, 8:00AM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new data related to its GITRL-Fc immuno-oncology therapeutic candidate at the American Association of Cancer Research (AACR) Meeting. OncoMed plans to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its GITRL-Fc candidate in late 2016/early 2017.
OMED: 12.57 (+0.44)
OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial for Demcizumab and Pembrolizumab (anti-PD1)
GlobeNewswire - Thu Mar 17, 7:30AM CDT
OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, today announced dosing of the first patient in its Phase 1b clinical trial of OncoMed's investigational agent demcizumab (anti-DLL4, OMP-21M18), with Merck's anti-Programmed Cell Death 1 (PD1) therapy pembrolizumab (KEYTRUDA(R)). The combination of these agents may act as a double blockade for cancer-induced immune suppression with potential application to a number of solid tumor cancers.
OMED: 12.57 (+0.44)
OncoMed to Present Data at the American Association of Cancer Research Annual Meeting 2016
GlobeNewswire - Wed Mar 16, 3:30PM CDT
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical anti-cancer stem cell and immuno-oncology therapeutic candidates in a total of five presentations at the upcoming American Association of Cancer Research (AACR) Meeting to be held April 16-20, 2016 in New Orleans, LA.
OMED: 12.57 (+0.44)
Why OncoMed Pharmaceuticals (OMED) Stock Might be a Great Pick
Zacks Equity Research - Zacks Investment Research - Mon Feb 01, 7:45AM CST
OncoMed Pharmaceuticals (OMED) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
OMED: 12.57 (+0.44)
OncoMed Tanks on Phase II Pancreatic Cancer Study Update
Zacks Equity Research - Zacks Investment Research - Wed Jan 27, 1:30PM CST
OncoMed Pharmaceuticals' (OMED) shares plunged 45% after it provided disappointing update on its pancreatic cancer candidate tarextumab.
OMED: 12.57 (+0.44), BXLT: 46.02 (-0.18), GSK: 45.24 (+0.17), ANIK: 51.80 (+1.88)
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Involving Possible Violations of Federal Securities Laws by the Board of OncoMed Pharmaceuticals, Inc.
BusinessWire - Mon Jan 25, 12:36PM CST
Levi & Korsinsky announces it has commenced an investigation of OncoMed Pharmaceuticals, Inc. (NASDAQGS: OMED) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
OMED: 12.57 (+0.44)
Why OncoMed Pharmaceuticals' Stock Crashed Today
George Budwell, The Motley Fool - Motley Fool - Mon Jan 25, 11:53AM CST
What : Shares of OncoMed Pharmaceuticals , a clinical-stage biotech, dropped by more than 46% today on heavy volume after an independent data safety monitoring board reported that the company's midstage pancreatic cancer drug, tarextumab, doesn't...
OMED: 12.57 (+0.44), GSK: 45.24 (+0.17)
Will 2016 Be Celgene Corporation's Best Year Yet?
Sean Williams, The Motley Fool - Motley Fool - Mon Jan 25, 9:38AM CST
Image source: NIH Image Gallery via Flickr. In a year in which the stock market was relatively flat, biotech blue-chip Celgene was a noted outperformer, having gained 5.5% over the 12 months. 2015 was yet another strong year of growth for the...
OMED: 12.57 (+0.44), CELG: 114.57 (+2.38)
OncoMed Provides Update on Tarextumab Phase 2 Pancreatic Cancer ALPINE Trial
GlobeNewswire - Mon Jan 25, 6:30AM CST
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, announced an update on the Phase 2 ALPINE clinical trial following a pre-planned January 23 interim efficacy assessment of the clinical trial by an independent data safety monitoring board (DSMB). The DSMB assessed data from 172 patients treated as of a January 6, 2016 data cutoff date.
OMED: 12.57 (+0.44)
OncoMed Presents Updated Phase 1b Data for Demcizumab in First-Line Pancreatic Cancer at the Gastrointestinal Cancers Symposium
GlobeNewswire - Fri Jan 22, 7:30AM CST
OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology therapeutics, announced updated survival data from the company's Phase 1b clinical trial of demcizumab (anti-DLL4, OMP-21M18) at the Gastrointestinal Cancers Symposium.
OMED: 12.57 (+0.44)
